Yuki Kato Maves, Hooman Izadi, Elvira Catherina Talaoc, Deborah Yan, Charlene Echegaray, Andrew Calinisan, Krystal Moya, Heather Venant, Mitchell Garland, Radhika Iyer, Shounak Ghosh, Stephanie Songco, Jayant Thatte, and Thomas Broudy
CrownBio has developed a syngeneic model screening platform to facilitate the preclinical efficacy testing of immuno-oncology agents in vivo (MuScreen™).
Having an in-depth understanding of the immune makeup of the syngeneic models in which immunomodulatory compounds are screened is paramount for successful translation into the clinic.
Our models have been fully characterized to investigate the correlation between responsiveness and effects of checkpoint inhibitors (e.g. anti-PD-1), and macrophage targeted agents (e.g. CSF1R inhibition) on immune infiltrates including tumor-associated macrophages (TAMs).